In an unprecedented move that has sent shockwaves through the pharmaceutical industry, Danish drugmaker Novo Nordisk launched an unsolicited ~$9 billion bid to acquire obesity-focused biotech Metsera, directly challenging a deal Pfizer had already secured. The aggressive counteroffer, announced on October 30, 2025, marks a dramatic escalation in the race to dominate the rapidly expanding weight-loss drug market and signals a strategic shift for Novo Nordisk under new leadership.
The Bidding War Intensifies
Pfizer and Novo Nordisk are engaged in a high-profile legal battle over the acquisition of Metsera, a clinical-stage biotech focused on obesity treatments. Pf...
